ThromboGenics awarded €3 million grant for research into DME treatment

ThromboGenics has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology to be used for research into potential new biotherapeutics for the treatment of diabetic macular edema, according to a press release. The therapeutics will be aimed at reducing vascular leakage and inflammation. ThromboGenics will use the grant funding to attempt to identify preclinical candidates that meet a target product profile based around in vitro potency, in vivo efficacy and drug-like properties, the release said.